Search
Poliovirus type 2 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10796ApprovedInvestigationalPoliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by
Acrivastine
go.drugbank.com/drugs/DB09488ApprovedAs an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension
Smallpox (Vaccinia) Vaccine, Live
go.drugbank.com/drugs/DB14711ApprovedInvestigational[L12747] ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.
Glisoxepide
go.drugbank.com/drugs/DB01289Investigationalby sulphate. … Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS) and
Acarbose
go.drugbank.com/drugs/DB00284ApprovedInvestigational[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels.
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalIt is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). … Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized by
Imiglucerase
go.drugbank.com/drugs/DB00053ApprovedInvestigationalAlglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.
Products: CEREZYME 400 U/10 ML İNFÜZYONLUK KONSANTRE ÇÖZELTİ İÇİN TOZ, CEREZYME 200 U INFUZYONLUK KONSANTRE ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADETHuperzine A
go.drugbank.com/drugs/DB04864ApprovedInvestigationalWithdrawnIt is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.